Back to Search
Start Over
Targeted therapies in bladder cancer: signaling pathways, applications, and challenges
- Source :
- MedComm, Vol 4, Iss 6, Pp n/a-n/a (2023)
- Publication Year :
- 2023
- Publisher :
- Wiley, 2023.
-
Abstract
- Abstract Bladder cancer (BC) is one of the most prevalent malignancies in men. Understanding molecular characteristics via studying signaling pathways has made tremendous breakthroughs in BC therapies. Thus, targeted therapies including immune checkpoint inhibitors (ICIs), antibody–drug conjugates (ADCs), and tyrosine kinase inhibitor (TKI) have markedly improved advanced BC outcomes over the last few years. However, the considerable patients still progress after a period of treatment with current therapeutic regimens. Therefore, it is crucial to guide future drug development to improve BC survival, based on the molecular characteristics of BC and clinical outcomes of existing drugs. In this perspective, we summarize the applications and benefits of these targeted drugs and highlight our understanding of mechanisms of low response rates and immune escape of ICIs, ADCs toxicity, and TKI resistance. We also discuss potential solutions to these problems. In addition, we underscore the future drug development of targeting metabolic reprogramming and cancer stem cells (CSCs) with a deep understanding of their signaling pathways features. We expect that finding biomarkers, developing novo drugs and designing clinical trials with precisely selected patients and rationalized drugs will dramatically improve the quality of life and survival of patients with advanced BC.
- Subjects :
- ADCs
bladder cancer
CSCs
ICIs
metabolism
TKIs
Medicine
Subjects
Details
- Language :
- English
- ISSN :
- 26882663
- Volume :
- 4
- Issue :
- 6
- Database :
- Directory of Open Access Journals
- Journal :
- MedComm
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.6e3cc1563cbc4abebd385f45a2f1eef0
- Document Type :
- article
- Full Text :
- https://doi.org/10.1002/mco2.455